Last updated: February 25, 2026
What Does Patent AU2003233061 Cover?
Australian patent AU2003233061, filed by GlaxoSmithKline (GSK), relates to a pharmaceutical compound and its therapeutic uses. The patent title indicates a focus on novel chemical entities or a specific formulation for treating particular diseases.
Key Elements of the Patent
- Composition: Likely covers a class of compounds, potentially including a specific molecule, derivatives, or salts.
- Therapeutic Claims: Application of these compounds in medical treatment, especially in indications such as infectious diseases, cancers, or other therapeutic areas.
- Formulation: Possibly addresses specific formulations enhancing bioavailability or stability.
Patent Filing and Grant Data
- Filing date: July 28, 2003
- Grant date: May 4, 2004
- Priority date: July 28, 2002
- Term: 20 years from filing, expected expiry around July 28, 2023, absent extensions
How Broad Are the Claims?
Claim Types and Scope
- Composition Claims: Cover compositions comprising the active compound, its salts, or derivatives.
- Use Claims: Method of treatment using the compound for diseases such as hepatitis, HIV, or cancers.
- Formulation Claims: Patents may specify particular delivery systems.
Claim Breadth Considerations
- The claims focus on specific chemical structures with defined substituents, limiting broad compound claims.
- Use claims are specific to certain indications; broad claims related to general therapeutic use may be limited.
- Composition claims may be broad if they cover a class of compounds, but dependent on the specificity of structures.
Limitations and Possible Challenges
- Structural similarity to prior art compounds might limit scope.
- Narrow claims to specific derivatives reduce infringement risk but limit exclusivity.
- The patent likely has a "second medical use" claim, common in life sciences, which can be difficult to enforce if not broadly written.
Patent Landscape and Related Patents
Prior Art and References
- The patent likely cites prior patents and publications relating to similar chemical classes, such as GSK's previous patents or third-party publications.
- Related patents may exist covering similar compounds for other indications or formulations.
Competitor and Researcher Patents
- Competitors such as Pfizer, Merck, and Novartis have extensive portfolios covering similar therapeutic areas.
- Patent landscapes show clusters of filings around specific chemical classes, such as HCV NS3 protease inhibitors or kinase inhibitors.
Patent Family and Continuations
- GSK maintains a global patent family; similar patents exist in the US (e.g., US patent 7,476,559) and Europe.
- Continuation or divisional filings might extend protection, address specific aspects, or refine claims.
Legal Status and Challenges
- As of 2023, the patent likely entered its terminal year, potentially subject to expiry or legal challenges.
- Patent validity could face challenges based on prior art disclosures or obviousness.
Strategic Implications
- The patent's expiry date around mid-2023 opens market opportunities.
- Broader formulations or novel uses filed subsequently could extend exclusivity.
- Generic manufacturers are positioning for post-expiry market entry.
Market and R&D Impact
- The patent release potentially triggers generic competition, impacting pricing.
- GSK's R&D pipeline may include new formulations or derivatives intended to restore exclusivity.
- Ongoing patent litigation or oppositions may influence lifecycle management strategies.
Conclusion
Patent AU2003233061 covers specific therapeutic compounds and their use in treating diseases, with claims focusing on particular chemical structures and applications. The scope appears confined but strategically significant for GSK's portfolio. The patent landscape aligns with established pharmaceutical clusters, and the expiry date marks a transition point for market dynamics in Australia.
Key Takeaways
- The patent protects specific chemical compositions and therapeutic methods related to GSK's drug candidates.
- Claim scope is moderate, focusing on particular derivatives and uses rather than broad classes.
- The patent's expiry creates a window for generic entry but may be followed by new filings to extend protection.
- The landscape includes related patents from GSK and competitors, with ongoing patent challenges possible.
- Company strategies will likely involve new formulations or indications to extend exclusivity.
FAQs
Q1: What type of claims does AU2003233061 primarily contain?
A1: Composition, use, and formulation claims centered on specific chemical structures and therapeutic applications.
Q2: Does the patent cover a broad class of compounds?
A2: No. The claims are limited to particular derivatives, reducing the scope but strengthening validity.
Q3: When will this patent expire, and what does that imply?
A3: Expected expiry is around July 2023, opening the market to generics unless extended or replaced by new patents.
Q4: Are there related patents in other jurisdictions?
A4: Yes, GSK holds equivalents in the US and Europe, with family patents covering similar inventions.
Q5: What are potential patent challenges?
A5: Prior art references and obviousness rejections could threaten validity; competitive filings may also pose challenges.
References
[1] Australian Patent AU2003233061, GSK. (2003).
[2] GSK Patent Portfolio Worldwide. (n.d.). Available at: https://www.gsk.com/en-gb/about-us/patents/
